Paris-based medtech startup Robeauté has raised $28 million in a funding round led by Plural, Cherry Ventures, and Kindred Ventures. This capital injection highlights growing investment in technologies addressing complex neurological challenges. The firm aims to revolutionize neurosurgery using microrobots designed for precision in diagnosis and treatment. With growing attention on minimally invasive medical technologies, the development reflects increased interest in solving issues related to neurological disorders. Robeauté’s planned expansion to the U.S. and focus on regulatory approval underscore its broader ambitions in the global healthcare market.
What are Robeauté’s microrobots designed for?
Robeauté’s microrobots, which are no larger than a grain of rice, are engineered to navigate curved pathways in the brain with high precision. They are capable of delivering molecules, implanting electrodes, and gathering critical data for treating neurological conditions. The company has spent eight years refining its technology, securing over 50 patents, and developing devices that combine a microscopic engine, propeller, and tracking system. Currently, the technology is undergoing animal testing as a biopsy tool, with future plans to expand its applications to include treatments and real-time monitoring.
How will the funding be utilized?
The recent funding will support Robeauté’s expansion into the U.S. market, including obtaining FDA approval and setting up operations. The company plans to initiate human trials by 2026 to further validate its technology. Additionally, the funds will boost ongoing product development efforts and collaborations with research and industrial laboratories. Strategic backing from Brainlab positions Robeauté to strengthen its focus on neurology and neurosurgery, while also benefiting from partnerships that enhance regulatory and market entry strategies.
Plural partner Ian Hogarth commented on the potential of Robeauté’s technology, stating,
“Robeauté’s technology doesn’t just have the potential to transform neurosurgery — it could also fundamentally change how drug companies find the best solutions for patients.”
This sentiment reflects the growing medical and commercial interest in microrobotics.
Robeauté’s journey began with founder Bertrand Duplat, who was inspired by personal experience when his mother was diagnosed with glioblastoma. Leveraging his extensive background in robotics and 3D software, Duplat, alongside co-founder Joana Cartocci, has built a specialized team to tackle limitations in current neurosurgical and pharmaceutical approaches.
In earlier reports, Robeauté was noted for its conceptual microrobot prototypes, which were in early development stages. Since then, the company has evolved significantly, progressing from initial designs to patent-secured devices undergoing animal trials. This marks a shift from concept exploration to actionable applications, reflecting its growing readiness for clinical environments and regulatory approval processes.
The medtech sector has long sought better solutions for overcoming the blood-brain barrier, a major challenge in delivering treatments for neurological disorders. Robeauté’s microrobots represent a potential step forward by combining precision navigation with modular adaptability. However, the company’s success will depend on clinical validation, regulatory approvals, and its ability to integrate data collected by the robots into meaningful treatments. These factors will ultimately determine how Robeauté’s solution impacts neurosurgical practices and patient care on a broader scale.
